INmune Bio, Inc.
INMB
$1.63
$0.000.00%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | 50.00K | 0.00 | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | 50.00K | 0.00 | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | 50.00K | 0.00 | -- |
| SG&A Expenses | 2.68M | 2.25M | 2.32M | 2.11M | 2.26M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 7.43M | 8.06M | 9.96M | 9.47M | 12.29M |
| Operating Income | -7.43M | -8.06M | -9.91M | -9.47M | -12.29M |
| Income Before Tax | -6.47M | -24.46M | -9.74M | -9.22M | -12.09M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -6.47M | -24.46M | -9.74M | -9.22M | -12.09M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -6.47M | -24.46M | -9.74M | -9.22M | -12.09M |
| EBIT | -7.43M | -8.06M | -9.91M | -9.47M | -12.29M |
| EBITDA | -7.42M | -- | -- | -- | -- |
| EPS Basic | -0.24 | -1.05 | -0.43 | -0.41 | -0.60 |
| Normalized Basic EPS | -0.17 | -0.21 | -0.27 | -0.26 | -0.37 |
| EPS Diluted | -0.24 | -1.05 | -0.43 | -0.41 | -0.60 |
| Normalized Diluted EPS | -0.17 | -0.21 | -0.27 | -0.26 | -0.37 |
| Average Basic Shares Outstanding | 26.59M | 23.30M | 22.50M | 22.25M | 20.19M |
| Average Diluted Shares Outstanding | 26.59M | 23.30M | 22.50M | 22.25M | 20.19M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |